Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin
- PMID: 16836499
- DOI: 10.1111/j.1468-3083.2006.01577.x
Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin
Abstract
Background: There are numerous studies that individually evaluate the efficacy/effectiveness and toxicity of drugs in the systemic treatment of psoriasis. On the contrary, we can hardly find studies that compare each other.
Objective: To evaluate and compare the effectiveness and toxicity of mycophenolate mofetil and cyclosporin in chronic plaque psoriasis through a prospective, sequential, cross-over, non-randomized, two-phase, open-label study.
Patients/methods: Eight patients (five women and three men; mean age 57, range 35-78) with moderate-to-severe chronic plaque psoriasis were included in the study. They were treated with oral mycophenolate mofetil (30 mg/kg/day) over a period of 16 weeks. Following a variable washout period and after a new outbreak of the disease, oral cyclosporin was introduced at a dose of 4 mg/kg/day. During both treatment regimens, follow-up visits were performed at 3, 8 and 16 weeks.
Results: In both groups, the PASI started to decrease once treatment was begun. Cyclosporin was faster and statistically a lot more effective than mycophenolate mofetil, reaching a higher number of complete remissions and better percentages of PASI improvement from baseline (45.7%, 60.2% and 60.5% at 3, 8 and 16 weeks respectively for mycophenolate mofetil, and 89.7%, 95.3% and 95.3% respectively at the same intervals for cyclosporin). Cyclosporin was also more predictable in its action as the percentage of improvement along the follow-up visits had a much wider range for mycophenolate mofetil. Overall, the tolerability of both drugs was good. None of the patients had to discontinue treatment because of an adverse event. Two patients treated with cyclosporin showed increased plasma levels of creatinine.
Conclusions: Cyclosporin is more effective, fast, and predictable in its effect than mycophenolate mofetil to control moderate-to-severe chronic plaque psoriasis. Both drugs are well tolerated in short courses of treatment.
Similar articles
-
Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1447-51. doi: 10.1111/j.1468-3083.2010.03667.x. J Eur Acad Dermatol Venereol. 2010. PMID: 20384673 Clinical Trial.
-
A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis.Dermatology. 2009;219(2):126-32. doi: 10.1159/000226134. Epub 2009 Jun 23. Dermatology. 2009. PMID: 19546522 Clinical Trial.
-
Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.Br J Dermatol. 2004 Jan;150(1):132-5. doi: 10.1111/j.1365-2133.2004.05563.x. Br J Dermatol. 2004. PMID: 14746627
-
Long-term safety of mycophenolate mofetil and cyclosporine: a review.J Drugs Dermatol. 2008 Aug;7(8):741-8. J Drugs Dermatol. 2008. PMID: 18720690 Review.
-
[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013. Hautarzt. 2000. PMID: 10743574 Review. German.
Cited by
-
New Insights in Psoriasis Management using Herbal Drug Nanocarriers.Curr Pharm Des. 2024;30(32):2550-2561. doi: 10.2174/0113816128330298240708110336. Curr Pharm Des. 2024. PMID: 39051579 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical